Ostarine - Interferon Alfa-2b Interaction

Interaction Details

Interferon Alfa-2b is classified as belonging to the following category: Hepatotoxic Drugs

Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Some clinical research shows that ostarine can increase alanine aminotransferase, a marker of liver damage, in some patients. Additionally, the U.S. Food and Drug Administration warns that supplements containing SARMs, such as ostarine, have been associated with reports of liver toxicity and there is at least one report of drug-induced liver injury in a 40-year-old male which was attributed to the use of ostarine for 2 months.

Interaction Rating

Likelihood of Occurrence

Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists

References

• Warning Letter: Ironmag Labs 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582464.htm Accessed: November 1, 2017
• Warning Letter: Panther Sports Nutrition 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm581630.htm. Accessed: November 1, 2017
• Warning Letter: Infantry Labs LLC 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582685.htm. Accessed: November 1, 2017
• Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14(4):335-45.
• Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II tri
• Bedi H, Hammond C, Sanders D, Yang HM, Yoshida EM. Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG Case Rep J 2021;8(1):e00518.

Interferon Alfa-2b Overview

• Interferon alfa-2b injection is used to treat a number of conditions.

• Interferon alfa-2b injection is used

  • alone or in combination with ribavirin (Copegus, Rebetol, Ribasphere) to treat chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in people who show signs of liver damage,

  • to treat chronic hepatitis B infection (swelling of the liver caused by a virus) in people who show signs of liver damage,

  • to treat hairy cell leukemia (a white blood cell cancer),

  • to treat genital warts,

  • to treat Kaposi's sarcoma (a type of cancer that causes abnormal tissue to grow on different parts of the body) related to acquired immunodeficiency syndrome (AIDS),

  • to treat malignant melanoma (a cancer that begins in certain skin cells) in certain people who have had surgery to remove the cancer,

  • along with another medication to treat follicular non-Hodgkin's lymphoma (NHL; a slow-growing blood cancer).

• Interferon alfa-2b is in a class of medications called immunomodulators. Interferon alfa-2b works to treat hepatitis C virus (HCV) and hepatitis B virus (HBV) by decreasing the amount virus in the body. Interferon alfa-2b may not cure hepatitis B or hepatitis C or prevent you from developing complications from these infections such as cirrhosis (scarring) of the liver, liver failure, or liver cancer. It also may not prevent the spread of hepatitis B or C to other people. It is not known exactly how interferon alfa-2b works to treat cancer or genital warts.

Ostarine - More Interactions

Ostarine interacts with 578 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.